Pharmico International

Pharmico International Corporation, in corroboration with NIH NIAID Chemical Countermeasures Research Program (CCRP) and the CounterACT Efficacy Research Facility (CERF) is preparing for Phase 1 testing of its patent pending treatment for Acute Lung Injury and Acute Respiratory Distress Syndrome under FDA Emergency Use Authorization (EUA) review. Docket No. ER-00751

The objective of the trial is to determine whether the treatment is efficacious and effective in reducing pulmonary edema and pleural effusion associated with hyaluronan dysregulation.  We believe reducing pulmonary edema and pleural effusion with our treatment will reduce the need for invasive intubation and ventilation. 

The pathophysiology of ALI/ARDS is driven by an aggressive inflammatory reaction. Indirect injury occurs as part of a systemic inflammatory response syndrome (SIRS) which could lead to Sepsis.  

ARDS is primarily caused by damage to the tiny blood vessels in your lungs. Fluid from these vessels leaks into the air sacs of the lungs. These air sacs are where oxygen enters and carbon dioxide is removed from your blood. When these air sacs fill with fluid, less oxygen gets to your blood.

Some common things that may lead to this type of lung damage include:

• Inhaling toxic substances, such as salt water, sulfur mustard, chemicals, smoke, and vomit

• Virus infections such as SARS-coV-2

• Developing a severe blood infection

• Developing a severe infection of the lungs, such as pneumonia

• Receiving an injury to the chest or head, such as during a car wreck or contact sports

• Overdosing on sedatives or tricyclic anti-depressantsELG Advantage

Acute Respiratory Distress Syndrome

• Acute respiratory distress syndrome (ARDS) is defined as hypoxemia secondary to a rapid onset of noncardiogenic pulmonary edema ​(Fig-1)​